231 426

Cited 0 times in

Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review

DC Field Value Language
dc.contributor.author구교철-
dc.contributor.author안현규-
dc.date.accessioned2021-05-21T17:02:23Z-
dc.date.available2021-05-21T17:02:23Z-
dc.date.issued2020-11-
dc.identifier.issn1661-6596-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182665-
dc.description.abstractMetformin, an oral biguanide used for first-line treatment of type 2 diabetes mellitus, has attracted attention for its anti-proliferative and anti-cancer effects in several solid tumors, including prostate cancer (PCa). Liver kinase B1 (LKB1) and adenosine monophosphate-activated protein kinase (AMPK) activation, inhibition of the mammalian target of rapamycin (mTOR) activity and protein synthesis, induction of apoptosis and autophagy by p53 and p21, and decreased blood insulin level have been suggested as direct anti-cancer mechanisms of metformin. Research has shown that PCa development and progression are associated with metabolic syndrome and its components. Therefore, reduction in the risk of PCa and improvement in survival in metformin users may be the results of the direct anti-cancer mechanisms of the drug or the secondary effects from improvement of metabolic syndrome. In contrast, some research has suggested that there is no association between metformin use and PCa incidence or survival. In this comprehensive review, we summarize updated evidence on the relationship between metformin use and oncological effects in patients with PCa. We also highlight ongoing clinical trials evaluating metformin as an adjuvant therapy in novel drug combinations in various disease settings.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.publisherINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntineoplastic Agents / therapeutic use-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use-
dc.subject.MESHApoptosis-
dc.subject.MESHAutophagy-
dc.subject.MESHBlood Glucose / metabolism-
dc.subject.MESHClinical Trials as Topic-
dc.subject.MESHCyclin-Dependent Kinase Inhibitor p21 / metabolism-
dc.subject.MESHDiabetes Complications / drug therapy-
dc.subject.MESHDiabetes Mellitus, Type 2 / drug therapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHHomeostasis-
dc.subject.MESHHumans-
dc.subject.MESHInsulin / metabolism-
dc.subject.MESHMale-
dc.subject.MESHMetabolic Syndrome / complications-
dc.subject.MESHMetabolic Syndrome / drug therapy*-
dc.subject.MESHMetformin / therapeutic use*-
dc.subject.MESHProstatic Neoplasms / complications-
dc.subject.MESHProstatic Neoplasms / drug therapy*-
dc.subject.MESHProtein Kinases / metabolism-
dc.subject.MESHProtein-Serine-Threonine Kinases / metabolism-
dc.subject.MESHRisk-
dc.subject.MESHTOR Serine-Threonine Kinases / metabolism-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTumor Suppressor Protein p53 / metabolism-
dc.titleCurrent Status and Application of Metformin for Prostate Cancer: A Comprehensive Review-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorHyun Kyu Ahn-
dc.contributor.googleauthorYoung Hwa Lee-
dc.contributor.googleauthorKyo Chul Koo-
dc.identifier.doi10.3390/ijms21228540-
dc.contributor.localIdA00188-
dc.relation.journalcodeJ01133-
dc.identifier.eissn1422-0067-
dc.identifier.pmid33198356-
dc.subject.keywordmetformin-
dc.subject.keywordprostatic neoplasm-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.affiliatedAuthor구교철-
dc.citation.volume21-
dc.citation.number22-
dc.citation.startPage8540-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.21(22) : 8540, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.